Antigen Seeding Technology (AST) is a Potent and Complimentary Addition to the Company’s Engineered Toxin Bodies (ETB) Technology
AUSTIN, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) — Molecular Templates, Inc., (Nasdaq: MTEM), a medical-degree oncology company targeted on the discovery and improvement of the organization’s proprietary engineered toxin our bodies (ETBs), which can be differentiated, centered, biologic therapeutics for most cancers, introduced the presentation today of a poster on its PD-L1 ETB with Antigen Seeding Technology (AST) at the continuing Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, currently taking region in Washington D.C.
Antigen Seeding Technology represents a singular immune-oncology technique leveraging the novel mechanism of action of Molecular Templates’ ETB era. ETBs engineered with Antigen Seeding Technology can hand over viral antigens as a payload inside the target tumor, resulting in the antigens being supplied at the cellular surface of the tumor cells in complicated with MHC-1. ETB therapeutics incorporating antigen seeding are designed to work through twin mechanisms of movement through redirecting a high avidity, pre-present antigen-unique cytotoxic T cell (CTL) response to the tumor at the same time as at the same inducing cell demise through the enzymatic and everlasting destruction of ribosomes. Coupling awesome mechanisms of tumor cellular killing into one ETB molecule offers the ability to grow target penetrance, increase an extended immune response, and overcome tumor resistance.
The poster, titled “Identification and Functional Profiling of PD-L1 Targeted Engineered Toxin Bodies for Antigen Seeding Technology (AST) and Redirection of T cellular Response to Tumors” summarizes a series of preclinical experiments conducted by Molecular Templates to create PD-L1 targeted ETBs which have antigen seeding residences and to investigate the mechanisms with the aid of which they are able to kill cancer cells.
“Antigen Seeding Technology represents a novel method to immune-oncology that can be lively in sufferers where widespread immune-oncology techniques had been exhausted,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive, and Scientific Officer. “We are currently accomplishing in vivo research with PD-L1 centered ETBs that have AST capability. We plan to report an IND and enter the hospital with our first PD-L1 ETB candidate using AST in 2019.”
Poster Presentation Details:
The poster (#P9) will be to be had to view in Hall E of the Walter E. Johnson Convention Center these days, Friday, Nov. 9 from eight a.M. – 8 p.M. And Saturday, Nov. 10 from 8 a.M. – 8:30 p.M. (all instances are E.T.)
The poster may be observed under “Clinical and Scientific Presentations” at http://ir.Mtem.Com/events-and-displays/displays.
Forward-Looking Statements
This press launch carries forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular disclaims any purpose or responsibility to update those ahead-searching statements and claims the protection of the Act’s Safe Harbor for ahead-searching statements. All statements, aside from statements of historical facts, protected in this press launch concerning the method, future operations, destiny financial function, destiny revenue, projected costs, prospects, plans, and goals of control are forward-searching statements. In addition, while or if used in this press launch, the phrases “can also,” “should,” “should,” “assume,” “believe,” “estimate,” “count on,” “intend,” “plan,” “predict” and comparable expressions and their variations, as they relate to Molecular, may also discover ahead-searching statements. Examples of such statements consist of, however, are not restrained to, statements regarding Molecular’s expectations with appreciation to its collaboration with Takeda and its supposed use of proceeds from the imparting.
Forward-searching statements aren’t ensured of destiny’s overall performance and contain dangers and uncertainties. Actual occasions or effects can also differ materially from the ones discussed within the forward-looking statements as a result of various factors along with, but not restrained to, the uncertainties inherent inside the preclinical and clinical development manner; whether Molecular’s coins assets may be enough to fund its persevering with operations for the duration and/or trials predicted; the ability of Molecular to defend its intellectual property rights; and legislative, regulatory, political and financial trends, as well as those risks identified underneath the heading “Risk Factors” in Molecular’s filings with the SEC. Any forward-looking statements contained on this press launch speak most effectively as of the date hereof, and Molecular particularly disclaims any duty to replace any forward-looking declaration, whether or not because of new records, future activities, or otherwise.
